Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 10,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This represents a 16.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Enliven Therapeutics Trading Up 1.7%

Shares of ELVN opened at $30.24 on Wednesday. The business’s 50-day moving average price is $25.88 and its 200 day moving average price is $22.02. The stock has a market capitalization of $1.81 billion, a P/E ratio of -16.26 and a beta of 0.33. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.78.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on ELVN shares. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in the company. Affinity Asset Advisors LLC acquired a new stake in Enliven Therapeutics in the second quarter valued at approximately $8,024,000. Candriam S.C.A. raised its holdings in shares of Enliven Therapeutics by 46.3% during the 3rd quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock valued at $12,473,000 after purchasing an additional 192,702 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Enliven Therapeutics by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock valued at $17,711,000 after purchasing an additional 63,580 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after purchasing an additional 410,034 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in Enliven Therapeutics by 177.4% during the second quarter. SG Americas Securities LLC now owns 36,373 shares of the company’s stock worth $730,000 after buying an additional 23,261 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.